ORPHA:370334
Extraskeletal Ewing sarcoma
Also known as: EOE · Extraosseous Ewing sarcoma · Extraosseous Ewing tumor · Extraskeletal Ewing tumor
Publications
1,160
Trials
6
Interventional, condition-specific
Researchers
1,088
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Extraskeletal Ewing sarcoma is a rare, poorly differentiated, highly malignant, soft tissue tumor, derived from neuroectoderm, that is morphologically indistinguishable from skeletal Ewing sarcoma but is located in extraosseous locations, with the most common being: chest wall, paravertebral region, abdominopelvic area (with predilection for the retroperitoneal space), gluteal region and lower extremities. Clinical presentation is highly variable and depends on tumor localization. Local recurrence is common and metastatic disease most frequently involves the bones and lungs.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018270
- UMLS:C0279980
- NCIT:C7135
Additional Mondo synonyms (11)
Extra-osseous Ewing's sarcoma · extraosseous Ewing sarcoma · extraosseous Ewing tumor · extraosseous Ewing tumour · extraosseous Ewing's sarcoma · extraosseous Ewing's tumor · extraosseous Ewing's tumour · extraskeletal Ewing sarcoma · extraskeletal Ewing tumor · extraskeletal Ewing tumour · extraskeletal Ewing's sarcoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,160 matched papers (600 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
6 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
1,160
1,160 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
1,160 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
600 in the last 10 years · low confidence
Phrase hits: 1,160 · MeSH hits: 0
Who's working on it?
1,088
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Zhang S4 papers · 2026
The First Clinical Medical College of Guangdong Medical University, Zhanjiang.
Papers in Europe PMC - 02Li W3 papers · 2025
Department of Medical Oncology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Papers in Europe PMC - 03Li Y3 papers · 2025
Ultrasound Medicine Center, Lanzhou University Second Hospital, Chengguan District, Lanzhou, 730030, Gansu, China.
Papers in Europe PMC - 04Liu X3 papers · 2025
Department of Pathology, the Second People's Hospital of Shenzhen, Guangdong Province (the First Affiliated Hospital of Shenzhen University), Shenzhen 518000, China.
Papers in Europe PMC - 05Singh A3 papers · 2025
Department of Radiation Oncology, RCC JIPMER, Puducherry, India.
Papers in Europe PMC - 06Wu Y3 papers · 2025
Department of Radiology, The Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Papers in Europe PMC - 07Zhang Y3 papers · 2025
Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, 467 Zhong Shan Road, Dalian, 116023, China.
Papers in Europe PMC - 08Abulihya M2 papers · 2024
Department of Pathology, Al-Istishari Arab Hospital, Ramallah, West Bank, Palestine.
Papers in Europe PMC - 09Alizadehasl A2 papers · 2024
Cardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
Papers in Europe PMC - 10Allali N2 papers · 2026
Radiology Department Mother and Child Hospital Ibn Sina, Rabat, Morocco.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
6
interventional trials for this specific condition
6 interventional trials matched this specific condition name; 1 currently recruiting in our sample. 161 trials are registered for Ewing sarcoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
6 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 89th percentile).
low confidence · 89th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
6 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06526897·NOT YET RECRUITING·Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma
Conditions: Adult Pleomorphic Rhabdomyosarcoma · AJCC Grade 2 Sarcoma · AJCC Grade 3 Sarcoma · Alveolar Soft Part Sarcoma·Matched via name phrase
Broader category: Ewing sarcoma
161
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06839703·NOT YET RECRUITING·International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma
Conditions: High-risk GD2-Positive Ewing Sarcoma·Matched via name phrase
- NCT06395103·RECRUITING·Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Conditions: B-cell Acute Lymphoblastic Leukemia · Diffuse Large B-cell Lymphoma · Burkitt Lymphoma · Neuroblastoma·Matched via name phrase
- NCT06926283·RECRUITING·A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
Conditions: Prostate Cancer · Other Solid Tumors · Ewing Sarcoma·Matched via name phrase
- NCT03715933·RECRUITING·Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Conditions: Ewing Sarcoma · Colorectal Adenocarcinoma·Matched via name phrase
- NCT07695311·NOT YET RECRUITING·EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT
Conditions: Ewing Sarcoma · Desmoplastic Small Round Cell Tumor·Matched via name phrase
- NCT04851119·RECRUITING·Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Conditions: Colorectal Carcinoma · Endometrial Carcinoma · Melanoma · Neuroblastoma·Matched via name phrase
- NCT06796543·RECRUITING·Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Conditions: Metastatic Sarcoma · Radiation Therapy Patient · Ewing Sarcoma · Rhabdomyosarcoma·Matched via name phrase
- NCT04055220·RECRUITING·Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
Conditions: Bone Sarcoma · Osteosarcoma · Ewing Sarcoma · Chondrosarcoma·Matched via name phrase
- NCT07172958·RECRUITING·Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Conditions: Rhabdomyosarcoma · Ewing Sarcoma · Neuroblastoma · Wilms Tumor·Matched via name phrase
- NCT06892678·RECRUITING·DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma
Conditions: Osteosarcoma Recurrent · Ewing's Tumor Recurrent·Matched via name phrase
- NCT07516353·NOT YET RECRUITING·my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults
Conditions: Sarcoma · Osteosarcoma · Ewing Sarcoma · Rhabdomyosarcoma·Matched via name phrase
- NCT04433221·RECRUITING·Combination Immunotherapy Targeting Sarcomas
Conditions: Sarcoma · Osteoid Sarcoma · Ewing Sarcoma·Matched via name phrase
- NCT06340204·RECRUITING·Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
Conditions: Ewing Sarcoma·Matched via name phrase
- NCT06699472·RECRUITING·A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib
Conditions: Ewing Sarcoma · Myelosuppression·Matched via name phrase
- NCT03356782·RECRUITING·Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
Conditions: Sarcoma · Osteoid Sarcoma · Ewing Sarcoma·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Extraskeletal Ewing sarcoma" OR "Extraosseous Ewing sarcoma" OR "Extraosseous Ewing tumor" OR "Extraskeletal Ewing tumor" OR "Extra-osseous Ewing's sarcoma" OR "extraosseous Ewing tumour" OR "extraosseous Ewing's sarcoma" OR "extraosseous Ewing's tumor" OR "extraosseous Ewing's tumour" OR "extraskeletal Ewing tumour" OR "extraskeletal Ewing's sarcoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Extraskeletal Ewing sarcoma" OR "Extraosseous Ewing sarcoma" OR "Extraosseous Ewing tumor" OR "Extraskeletal Ewing tumor" OR "Extra-osseous Ewing's sarcoma" OR "extraosseous Ewing tumour" OR "extraosseous Ewing's sarcoma" OR "extraosseous Ewing's tumor" OR "extraosseous Ewing's tumour" OR "extraskeletal Ewing tumour" OR "extraskeletal Ewing's sarcoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 6 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"Ewing sarcoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: EOE
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (1160) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T14:56:06.641Z
